GAMMA Investing’s Eledon Pharmaceuticals ELDN Stock Holding History

GAMMA Investing’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.68K	Hold	1,188	–	–	﹤0.01%	3495
2026 Q1	$3.66K	Buy	+1,188	New	+$2.8K	﹤0.01%	3486

Other funds holding ELDN

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

GAMMA Investing's ELDN Position: Q2 2026 in Review

GAMMA Investing held its Eledon Pharmaceuticals (ELDN) position steady in Q2 2026 at 1,188 shares worth $4.68K. The position accounts for ﹤0.01% of the portfolio, ranked #3495.

GAMMA Investing first reported a position in ELDN in Q1 2026 and has held it in 2 quarters since. 160 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

GAMMA Investing held 1,188 shares of Eledon Pharmaceuticals worth $4.68K as of Q2 2026.
GAMMA Investing left its Eledon Pharmaceuticals share count unchanged in Q2 2026.
Eledon Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3495 holding.
GAMMA Investing first reported a position in Eledon Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
160 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.